ADVR scientists will be working with the Department of Chemistry and Chemical Biology to identify how compounds such as AVR118, a Phase II clinical candidate, interact with clinically relevant molecular targets associated with cancer.
In addition to providing greater clarity into how AVR118 exerts its cytoprotective effects, this work is expected to provide valuable insights for producing new generations of product with greater potency and ease of administration.
Another important goal of this agreement is to apply ADVR's innovative AFP Technology to identify new compounds with anti-cancer activity.
In combination with Northeastern's MS and NMR analytical capabilities, the AFP Technology is expected to improve the efficiency of discovering new lead compounds.
“We are excited to be working with this prestigious research institution. Northeastern’s academic environment provides an ideal setting for advancing our understanding of AVR118’s clinical activity and furthering our oncology discovery efforts,” said Vincent P. Gullo, Ph.D., Chief Scientific Officer of ADVR.
Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to the discovery and development of small molecule anti-cancer drugs. Its lead compound, AVR118, represents a new class of cytoprotective agent that targets, among other things, some of the most problematic symptoms associated with clinical cachexia or the so called wasting syndrome. In addition, AVR118 has also been shown to possess topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.